Cecilia Brown

Lung Cancers Today

The Lung Cancer Research Foundation&reg; (LCRF) has announced its 2024 Scientific Grant Program award will fund $3.55 million in new research, marking &ldquo;the largest single-year investment in its history.&rdquo;&ldquo;Because research is LCRF&rsquo;s True North, we are committed to supporting science that seeks solutions to lung cancer&rsquo;s most challenging issues and unmet needs,&rdquo; said Kathryn O&rsquo;Donnell, PhD, chair of LCRF&rsquo;s Scientific Advisory Board and Associate Professor, Molecular Biology, UT Southwestern Medical Center, in a statement. &ldquo;Funding the most innovative research will ultimately lead to improved outcomes for patients with lung cancer.&rdquo;The LCRF 2024 research&nbsp;grants and awardees are:Leading Edge Grant Program: 
Lindsay LaFave, PhD,&nbsp;Albert Einstein College&nbsp;of Medicine, Bronx, New York 
William C. Rippe&nbsp;Award for Distinguished Research in Lung Cancer recipient 
Investigating chromatin-mediated mechanisms of immune response in lung cancerDian Yang, PhD,&nbsp;Columbia University&nbsp;Irving Medical Center, New York, New York 
James B. Dougherty, MD Award for Scientific Merit recipient 
Investigating the molecular basis of cancer plasticity in LKB1-mutant lung adenocarcinomaMinority Career Development Award (CDA): 
Tikvah Hayes, PhD, David Geffen School of Medicine at&nbsp;UCLA 
Cynthia M. Page Merit Award for Innovation in Lung Cancer recipient 
Advancing preclinical cell line diversity and decoding TKI-resistance landscapes in EGFR-mutant lung cancerLuisa Escobar-Hoyos, MSc, PhD,&nbsp;Yale University, New Haven, Connecticut 
Altered RNA splicing as a driver of Osimertinib resistance in lung cancerResearch Grant on Early Detection and Pre-Neoplasia in Lung Cancer: 
Peggy Hsu, MD, PhD,&nbsp;University of Michigan, Ann Arbor 
Understanding the origin of ALK-driven lung cancerResearch Grants on Understanding Resistance in Lung Cancer: 
William Feng, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts 
Targeting AP-1 in KRAS-mutant lung cancerMegan Burger, PhD, Oregon Health &amp; Science University, Portland 
Optimizing immunotherapy sequencing to overcome resistanceIASLC-LCRF Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers: 
David A. Barbie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts 
Aaron Hata, MD, PhD,&nbsp;Massachusetts&nbsp;General Hospital&ndash;Harvard Medical School, Boston 
Pasi J&auml;nne, MD, PhD, Dana-Farber Cancer Institute&ndash;Harvard University, Boston, Massachusetts 
Shunsuke Kitajima, PhD, the Japanese Foundation for Cancer Research, Tokyo 
Eric Smith, MD, PhD, Dana-Farber Cancer Institute&ndash;Harvard University, Boston, Massachusetts 
Immune elimination of drug tolerant persister cells in oncogene-driven lung cancerLCRF awarded its grants for projects that &ldquo;demonstrate profound promise to make a sustained and lasting impact on lung cancer research and outcomes,&rdquo; organizers said, noting that the grants are made possible by Research ALK+ve Lung Cancer UK, the LRE Foundation, and &ldquo;numerous generous donations from LCRF&rsquo;s supporters.&rdquo;&ldquo;Each year, our Scientific Advisory Board and Research Advocates review hundreds of submissions,&rdquo; said Colleen Conner Ziegler, Chair of LCRF&rsquo;s Board of Directors, in a statement. &ldquo;This ensures that LCRF is funding projects that will have the greatest impact on the lung cancer community and improve patient outcomes, both in the short and long term.&rdquo;Several awardees and investigators shared what the grants mean to them and their research programs.&ldquo;This LCRF Leading Edge Research Grant will enable my lab to investigate the molecular mechanisms driving cancer plasticity in Lkb1-mutant lung adenocarcinoma, shedding light on potential strategies for developing innovative treatments,&rdquo; Dr. Yang said in a statement about receiving the James B. Dougherty, MD Award for Scientific Merit as part of the Leading Edge Research Grant Program.Dr. LaFave, who received the William C. Rippe Award for Distinguished Research in Lung Cancer for investigating chromatin-mediated mechanisms of immune response in lung cancer, explained what she hopes to accomplish with the grant.&ldquo;I am honored to receive the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation,&rdquo; Dr. LaFave said in a statement. &ldquo;Thanks to the support from LCRF we hope to better understand differences in immunity in individuals with and without a smoking history to improve immunotherapy outcomes in lung cancer.&rdquo;Dr. Hayes, who received the Cynthia M. Page Merit Award for Innovation in Lung Cancer Research for her project on advancing preclinical cell line diversity and decoding TKI-resistance landscapes in EGFR-mutant lung cancer, shared what it meant to her to receive the grant.&ldquo;Thank you to LCRF and the LRE Foundation for this meritorious award,&rdquo; Dr. Hayes said in a statement. &ldquo;I&rsquo;m hopeful that we will develop innovative models and tools to assess the underlying biology of EGFR-mutant lung cancers.&rdquo;Source: <a href="https://www.prnewswire.com/news-releases/lung-cancer-research-foundation-announces-2024-scientific-research-grant-awards-302327606.html" target="_blank" rel="noopener">PR Newswire</a>

The Oncology Forum: Lung Cancer Experts Unpack Key NSCLC Data From ASCO 2025

Non-Small Cell Lung Cancer

Raffaele Califano, MD

MARIPOSA-2: How Baseline Mechanisms of Osimertinib Resistance Influence Outcomes in NSCLC

EGFR+ NSCLC

Laura Litwin

How Is Oligoprogressive Disease Managed in Patients With EGFR-Positive NSCLC?

Cheryl Czerlanis, MD

Lung Cancer Risk: The Role of Family History and Germline Genetic Alterations

ASCO 2025

Molly Li, MBBS

AI-Based Lung Cancer Screening: Molly Li, MBBS, Shares Insights From the LC-SHIELD Study

FDA Grants Approval of Taletrectinib for ROS1-Positive NSCLC

Latest News

Lung Cancer Research Foundation® Announces 2024 Scientific Grant Program Awards

The Lung Cancer Research Foundation® (LCRF) has announced its 2024 Scientific Grant Program award will fund $3.55 million in new research in lung cancer.